Roivant Sciences Ltd. Common Shares vs Toast Inc. Class A Common Stock — how do they compare? Roivant Sciences Ltd. Common Shares trades at $33.62 (market cap $24.99B), while Toast Inc. Class A Common Stock trades at $29.65 (market cap $17.85B). The key difference: Roivant Sciences Ltd. Common Shares is the larger of the two by market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Toast Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roivant Sciences Ltd. Common Shares for 3 Days and Toast Inc. Class A Common Stock for 0 Days on average.
| ROIV | TOST | |
|---|---|---|
Market Cap | $24.99B | $17.85B |
Volume | 4,711,562 | 6,311,718 |
Sector | Health | Technology |
52-Week High | $41.81 | $39.02 |
52-Week Low | $16.99 | $22.33 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $21.25B | $16.10B |
Signals from Pluang's Aura AI — not financial advice
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.
The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.
Read more on TOST →